This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cunningham, J. M. Articles by Goode, E. L. Search for Related Content PubMed PubMed Citation Articles by Cunningham, J. M. Articles by Goode, E. L.

Performance of Amplified DNA in an Illumina GoldenGate BeadArray Assay

¹ College of Medicine, Mayo Clinic, Rochester, Minnesota; ² H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida; ³ Duke University, Durham, North Carolina; and ⁴ Alberta Cancer Board, Calgary, Alberta

Requests for reprints: Ellen L. Goode, Department of Health Sciences Research, College of Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905. Phone: 507-266-7997; Fax: 507-266-2478. E-mail: egoode{at}mayo.edu

Whole genome amplification (WGA) offers a means to enrich DNA quantities for epidemiologic studies. We used an ovarian cancer study of 1,536 single nucleotide polymorphisms (SNPs) and 2,368 samples to assess performance of multiple displacement amplification (MDA) WGA using an Illumina GoldenGate BeadArray. Initial screening revealed successful genotyping for 93.4% of WGA samples and 99.3% of genomic samples, and 93.2% of SNPs for WGA samples and 96.3% of SNPs for genomic samples. SNP failure was predicted by Illumina-provided designability rank, %GC (P 0.002), and for WGA only, distance to telomere and Illumina-provided SNP score (P 0.002). Distance to telomere and %GC were highly correlated; adjustment for %GC removed the association between distance to telomere and SNP failure. Although universally high, per-SNP call rates were related to designability rank, SNP score, %GC, minor allele frequency, distance to telomere (P 0.01), and, for WGA only, Illumina-provided validation class (P < 0.001). We found excellent concordance generally (>99.0%) among 124 WGA:genomic replicates, 15 WGA replicates, 88 replicate aliquots of the same WGA preparation, and 25 genomic replicates. Where there was discordance, it was across WGA:genomic replicates but limited to only a few samples among other replicates suggesting the introduction of error. Designability rank and SNP score correlated with WGA:genomic concordance (P < 0.001). In summary, use of MDA WGA DNA is feasible; however, caution is warranted regarding SNP selection and analysis. We recommend that biological SNP characteristics, notably distance to telomere and GC content (<50% GC recommended), as well as Illumina-provided metrics be considered in the creation of GoldenGate assays using MDA WGA DNA. (Cancer Epidemiol Biomarkers Prev 2008;17(7):1781–9)

This article has been cited by other articles:

				E. L. Goode, B. L. Fridley, R. A. Vierkant, J. M. Cunningham, C. M. Phelan, S. Anderson, D. N. Rider, K. L. White, V. S. Pankratz, H. Song, et al. Candidate Gene Analysis Using Imputed Genotypes: Cell Cycle Single-Nucleotide Polymorphisms and Ovarian Cancer Risk Cancer Epidemiol. Biomarkers Prev., March 1, 2009; 18(3): 935 - 944. [Abstract] [Full Text] [PDF]